HBOT vs Red Light Therapy: Which Is Better for Recovery?
Buy the panel. Red light therapy scores 8.0 against HBOT's 6.2, costs $17 to $43 a month against $3,000 to $6,000, and does not lose a single use…
- Hyperbaric Oxygen Therapy
- Red Light Therapy
Best Interventions for Chronic Pain, Ranked by Evidence
Every intervention Outliyr has scored for chronic pain, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for chronic pain; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
49 of 91 evaluated interventions score 3.0+ out of 10 for chronic pain · 4 comparisons
Ranked for Chronic Pain
Category
-
Infrared Sauna
A 7.5/10 for chronic-pain fits Infrared Sauna because Oosterveld 2009 supports direction more than certainty. The existing rationale points to this narrower claim: this verified source studied infrared sauna in rheumatoid arthritis…
Read the Infrared Sauna report → -
Whole-Body Vibration
Whole-Body Vibration receives a 7.5/10 rating for the chronic-pain use case, reflecting a meta-analysis of ten randomized trials that reported significant reductions in pain and disability Zafar 2024. Whole-Body Vibration appears to…
Read the Whole-Body Vibration report → -
Red Light Therapy
Chronic-pain scoring lands at 7.0/10 because Fan 2024 supports osteoarthritis pain reduction across RCTs, even with certainty limits. Red Light Therapy is most convincing for chronic joint, tendon, and inflammatory pain where…
Read the Red Light Therapy report → -
PEMF (Pulsed Electromagnetic Field Therapy)
PEMF (Pulsed Electromagnetic Field Therapy) gets 7.0/10 for chronic pain; the evidence supports a narrow read. OA, lumbar, and chronic musculoskeletal pain show consistent but heterogeneous benefit. Cochrane 2013 concluded electromagnetic fields…
Read the PEMF (Pulsed Electromagnetic Field Therapy) report → -
Earthing
The evidence base for Earthing in chronic-pain scores 7.0/10, with Sokal et al. 2025 reporting greater postoperative VAS pain reduction than sham. Earthing as a grounding intervention shows modest analgesic signals in…
Read the Earthing report → -
Celebrex (Celecoxib)
The chronic pain case for Celebrex (Celecoxib) lands at 7.0/10 because the evidence points to a plausible use case without proving a universal response. Zeng X et al. 2026 is the best…
Read the Celebrex (Celecoxib) report → -
Vagus Nerve Stimulation
A 6.3/10 chronic pain rating fits Vagus Nerve Stimulation, since Clancy et al. 2014 points to a real but bounded effect. Duff 2024 found chronic pain results favoring auricular VNS, while Paccione…
Read the Vagus Nerve Stimulation report → -
TB-500 (Thymosin Beta-4 Fragment)
TB-500 (Thymosin Beta-4 Fragment) fits chronic pain at 6.2/10 when the baseline problem is real. Chronic-pain benefit is indirect through tissue recovery and inflammation modulation. Chronic tendinopathy reports are common, but no…
Read the TB-500 (Thymosin Beta-4 Fragment) report → -
Neurofeedback
For chronic pain, the 6.0/10 score reflects how Neurofeedback performs in Ostinelli et al. 2025. Chronic pain may respond through central pain modulation, sleep improvement, and autonomic downshifting. Evidence is not strong…
Read the Neurofeedback report → -
Molecular Hydrogen
Evidence for Molecular Hydrogen in chronic pain lands at 6.0/10 because Jamialahmadi 2024 reports 7 trials; reported reductions in total cholesterol, triglycerides, and LDL, with no significant HDL change. Ye 2026 points…
Read the Molecular Hydrogen report → -
Full-Body EMS
The chronic pain score is 6.0/10, and Full-Body EMS needs careful framing. Konrad 2025 supports a favorable chronic nonspecific low back pain signal, with pain and function improvements in pooled WB-EMS studies.…
Read the Full-Body EMS report → -
Ozone Therapy
The strongest chronic pain argument for Ozone Therapy is 6.0/10 because Lima 2024 reports Verified audit Track 1 source; six clinical trials with positive diabetic-foot-ulcer signals and considerable risk-of-bias caveats. Chang 2024…
Read the Ozone Therapy report → -
Curcumin
Most of curcumin's pain benefit rides on the osteoarthritis data, where a 2019 head-to-head RCT by Shep and colleagues found curcumin roughly matched diclofenac for knee pain over 28 days with better…
Read the Curcumin report → -
Hyperbaric Oxygen Therapy
Fibromyalgia and CRPS evidence support the chronic pain use case more than generic wellness slugs. Efrati 2015 reports tender-point reduction and quality-of-life gains after forty hard-chamber sessions. Niezgoda 2025 reviews CRPS evidence…
Read the Hyperbaric Oxygen Therapy report → -
HRV Biofeedback
The use-case math gives HRV Biofeedback 5.5/10 for chronic pain, guided by Eddie et al. 2025. VA studies show reduced perceived pain in veterans; mechanism via vagal anti-nociceptive pathways. The score stays…
Read the HRV Biofeedback report → -
Zone 2 Cardio
The chronic-pain case for Zone 2 Cardio is 5.5/10 because Lang 2024 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Moderate aerobic exercise can reduce chronic…
Read the Zone 2 Cardio report → -
Blood-Flow Restriction Training
In chronic pain, Blood-Flow Restriction Training rates 5.5/10 because Miller et al. 2021 supports selective use. BFR is used in chronic pain rehabilitation because low loads can preserve strength work when heavy…
Read the Blood-Flow Restriction Training report → -
Glycine
Glycine chronic pain earns 5.5/10 because Soh 2024 anchors the most relevant signal. Glycine fits chronic pain because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the…
Read the Glycine report → -
BPC-157
BPC-157 chronic pain earns 5.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits chronic pain when the target is tissue repair, vascular recruitment, or inflammation control, but the case still…
Read the BPC-157 report → -
Tirzepatide
Chronic pain can improve indirectly when weight loss reduces joint load and inflammation. Obesity related osteoarthritis patterns benefit most. There is no tirzepatide chronic pain RCT as the main indication. Retatrutide TRIUMPH…
Read the Tirzepatide report → -
Semaglutide
Chronic-pain scoring is 5.5/10 because Bliddal 2024 supports knee osteoarthritis pain improvement in people with obesity, but Semaglutide is not a broad analgesic. Pain improves most when mechanical load and inflammation are…
Read the Semaglutide report → -
Traditional Sauna (Finnish Dry-Heat)
Chronic pain scores 5.0/10. The systematic review by Hussain 2018 noted symptomatic benefit for rheumatological conditions and pain across several included studies, and heat is one of the oldest comfort measures for…
Read the Traditional Sauna (Finnish Dry-Heat) report → -
Omega-3
Mechanistically, Omega-3 scores 5.0/10 for chronic pain because the evidence points to a plausible use case without proving a universal response. Xie et al. 2025 is the best anchor here because it…
Read the Omega-3 report → -
Quercetin
Shoskes 1999 randomized 30 men with chronic prostatitis or chronic pelvic pain syndrome to 500 mg quercetin twice daily for 1 month, with 67 percent responding versus 20 percent on placebo by…
Read the Quercetin report → -
Ca-AKG (Calcium Alpha-Ketoglutarate)
Ca-AKG (Calcium Alpha-Ketoglutarate)'s 5.0/10 chronic-pain score starts with Demidenko 2021, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Anti-inflammatory mechanism is chronic-pain-adjacent, but there are…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report → -
Rapamycin
PEARL female pain improvement is interesting, but chronic-pain scoring should remain low-to-moderate until replicated.
Read the Rapamycin report → -
Essential Amino Acids
No direct chronic-pain evidence was verified. Mobility and strength improvements may indirectly reduce some pain burden in frail users.
Read the Essential Amino Acids report → -
Collagen Peptides
Joint pain reduction is the main pain endpoint. UC-II, eggshell membrane, and specific collagen peptide trials support modest joint-pain benefit, but general chronic pain outside joints is unsupported.
Read the Collagen Peptides report → -
Metformin
Metformin may indirectly reduce diabetes-related neuropathic risk through glycemic control, but B12 depletion can complicate neuropathy. Direct chronic-pain evidence remains weak.
Read the Metformin report → -
Ketogenic Diet
Chronic pain may improve indirectly in insulin-resistant or higher-weight users through weight loss, glycemic stabilization, and lower inflammatory load. Evidence in fibromyalgia, migraine, and inflammatory pain remains early. Strict keto can also…
Read the Ketogenic Diet report → -
ARA-290 (Cibinetide)
Chronic neuropathic pain has real but weaker support than the nerve-structure signal. The sarcoidosis pilot improved the Small Fiber Neuropathy Screening List score significantly versus placebo, per Heij 2012, and the type-2-diabetes…
Read the ARA-290 (Cibinetide) report → -
Methylene Blue
Chronic-pain claims are still weak for consumer oral use. Wickramasinghe 2025 and Zhu 2025 focus on short postoperative windows, so fibromyalgia or chronic-pain extrapolation remains mostly anecdotal.
Read the Methylene Blue report → -
Full-Spectrum Hemp (CBD)
Chronic pain lands at 4.4/10 because the highest-certainty cannabinoid pain reviews are equivocal. A PRISMA systematic review of 12 human CBD pain studies per Villanueva 2022 concluded the evidence remains insufficient and…
Read the Full-Spectrum Hemp (CBD) report → -
Pentosan Polysulfate (Elmiron)
Chronic pain is the core approved use, and it is also where the evidence splits. For interstitial cystitis bladder pain a pooled meta-analysis of six placebo-controlled trials found modest but real improvement…
Read the Pentosan Polysulfate (Elmiron) report → -
GHK-Cu
Chronic-pain stays at 4 because anti-inflammatory and anti-fibrotic mechanisms could matter in painful tissue remodeling, but human pain trials are not confirmed. He 2024 supports fibrosis biology, not analgesia.
Read the GHK-Cu report → -
Thymosin Beta-4 (Tβ4)
Chronic pain has no Tβ4-specific human RCT. The case rests on the secondary effects of better tissue repair and inflammation control, which are indirect rather than analgesic mechanisms; for nerve pain specifically…
Read the Thymosin Beta-4 (Tβ4) report → -
TRT (Testosterone Replacement Therapy)
Chronic pain and hypogonadism can overlap, especially with opioids or frailty, but TRT is not first-line pain care. Consider it only when low testosterone is clearly documented and symptoms fit.
Read the TRT (Testosterone Replacement Therapy) report → -
Retatrutide
Pain benefit is likely indirect through weight loss and reduced joint load. Knee osteoarthritis is the most relevant signal, but retatrutide is not a general analgesic and chronic pain endpoints remain narrow.
Read the Retatrutide report → -
Norwegian 4×4
Aerobic exercise can help chronic-pain management, but HIIT tolerability varies. Bike or pool alternatives may be better entry points than treadmill intervals.
Read the Norwegian 4×4 report → -
Saffron
Chronic-pain support is limited to dysmenorrhea and symptom-overlap contexts rather than broad pain syndromes; saffron is not a primary analgesic intervention.
Read the Saffron report → -
Astaxanthin
May help inflammatory background load, but chronic pain requires domain-specific treatment and evidence is indirect.
Read the Astaxanthin report → -
Rucking (Weighted Walking)
Mixed. Graded aerobic activity can help some chronic pain, but adding spinal and joint load is the wrong direction for many low-back and knee pain patterns; individualize with a clinician.
Read the Rucking (Weighted Walking) report → -
Sprinting (Sprint Interval Training)
Aerobic exercise can help chronic-pain management, but maximal sprint tolerability varies; lower-intensity entry points are usually better starts.
Read the Sprinting (Sprint Interval Training) report → -
Ashwagandha
Chronic-pain support is modest. Anti-inflammatory pathways and v0 joint-pain data justify the score, but ashwagandha is not an analgesic and lacks broad pain-condition RCT depth. Consider it adjunctive only when stress or…
Read the Ashwagandha report → -
Hyaluronic Acid
Indirect via osteoarthritis joint comfort per de Carvalho 2024; not a general analgesic and weak outside joint pain.
Read the Hyaluronic Acid report → -
Shilajit
Anti-inflammatory and bone-joint signals may matter for some chronic pain contexts, but direct chronic-pain RCTs are absent.
Read the Shilajit report → -
Tongkat Ali
Cortisol and stress modulation are chronic-pain-adjacent, but no direct pain RCT supports a therapeutic claim.
Read the Tongkat Ali report → -
Fucoidan (Brown Seaweed Polysaccharide)
Pain meta-analysis is animal-only; no human pain-outcome trials for fucoidan.
Read the Fucoidan (Brown Seaweed Polysaccharide) report → -
C60 (Buckminsterfullerene)
C60 chronic-pain scoring stays at 3.0 because no trial has tested pain scales, inflammatory pain, neuropathy, osteoarthritis, or analgesic use. Anecdotal pain relief appears intermittently in forums but is not systematic. The…
Read the C60 (Buckminsterfullerene) report →
Nothing matches those filters.
Comparisons that judge chronic pain
Head-to-head reports and category rankings that name a winner on this use case.
PEMF vs Red Light Therapy: Which Is Better for Pain?
Red light therapy scores 8.0 and PEMF 7.5, so the panel is the better first buy for most people. PEMF wins on bone and joint pain, where a…
- PEMF
- Red Light Therapy
HBOT vs Ozone Therapy: Which Is Better for Pain Relief?
HBOT scores 6.2 and ozone 5.1, but ozone wins several use cases outright. Pick HBOT for wounds, cognition and neuro recovery, at $3,000 to $6,000 a month. Pick…
- Hyperbaric Oxygen Therapy
- Ozone Therapy
Red Light Therapy vs Infrared Sauna: Which Should You Buy?
Red light therapy scores 8.0 and infrared sauna 7.4, so buy the panel first. It costs less, targets skin, hair, joints and recovery directly, and carries higher evidence…
- Red Light Therapy
- Infrared Sauna
Questions about chronic pain
What scores highest for chronic pain?
Infrared Sauna, at 7.5 out of 10 for chronic pain. A 7.5/10 for chronic-pain fits Infrared Sauna because Oosterveld 2009 supports direction more than certainty.
What is the cheapest thing that works for chronic pain?
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5 out of 10 for chronic pain.
How many interventions has Outliyr scored for chronic pain?
49 of the 91 interventions evaluated for chronic pain score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
